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Abstract
Primary antiphospholipid syndrome (APS) is a well-defined entity characterized by spontane-
ous and recurrent abortion, thrombocytopenia and recurrent vascular thromboses (arterial
and venous). Left ventricular thrombus mimicking primary cardiac tumor with recurrent
systemic embolism has not been previously reported.
In this report we describe a 39 year-old man admitted to hospital presenting with left hemi-
paresis and a peripheral embolism. He had no history of thrombotic events. Transthoracic
echocardiography showed a large, polypoid and mobile mass (4.0 × 1.2 cm) attached to the
apex of the left ventricle, highly suggestive of primary cardiac tumor. The patient subsequently
underwent open heart surgery. The histological examination showed an older thrombus and
a fresh thrombus. Post-operative laboratory tests showed lupus anticoagulant activity, con-
firming the primary APS diagnosis. The patient initiated treatment with oral anticoagulation
(INR levels between 2 and 3) and was discharged 29 days after surgery. At ten month follow-
-up, he was symptom-free with long-term anticoagulation therapy. No evidence of intracardiac
mass recurrence on two-dimensional echocardiography was seen.
Intracardiac thrombus has been rarely reported as a complication of primary APS. Left ven-
tricular mass mimicking primary cardiac tumor with recurrent systemic embolism has not
been previously reported. Pre-operative investigations could not distinguish such a thrombus
from a cardiac tumor and the diagnosis was made post-operatively. (Cardiol J 2009; 16, 6: 560–563)
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Introduction
Antiphospholipid syndrome (APS) is character-
ized by spontaneous abortion, thrombocytopenia and
recurrent vascular thromboses (arterial and venous)
in association with medium to high titers of antiphos-
pholipid (APL) antibodies or the demonstration of
a positive lupus anticoagulant (LA) test. This disorder
is referred to as primary APS when it occurs alone
[1]. Less well known is the association between APL
antibodies and primary intracardiac thrombosis.
Left ventricular giant thrombus mimicking
a primary cardiac tumor with recurrent systemic
embolism in a patient with primary antiphospholi-
pid syndrome has not been previously reported.
Case report
In this report we describe a 39 year-old man
admitted to hospital presenting with left hemipare-
sis and peripheral embolism. Physical examination
revealed a blood pressure of 120/70 mm Hg, heart
rate of 80 bpm and 16 breaths/min. Heart sounds
were regular and distant. No murmurs or rubs were
noted. Jugular venous pressure was normal. Lungs
were clear, abdomen soft and no peripheral edema
was found. Neurological examination revealed left
hemiparesis. The chest X-ray film and a 12-lead
electrocardiogram were unremarkable. Colour Dop-
pler ultrasound and duplex scan of the lower limb
ruled out deep venous thrombosis.
Two-dimensional transthoracic echocardiogra-
phy revealed a normal left ventricular and left atri-
um dimensions, there were no wall motion abnor-
malities, heart valve abnormalities were not seen,
with no evidence of vegetation. A large, polypoid
and mobile mass (4.0 × 1.2 cm) was seen attached
to the apex of the left ventricle, which suggested
a primary cardiac tumor (Fig. 1A).
In view of these findings and the history of re-
current systemic embolism, the patient subsequent-
ly underwent open heart surgery. On cardiopulmo-
nary bypass, the left ventricle was opened and
a large mass was identified attached to the apex of
the left ventricle. The gross examination of the
operative specimen revealed multiple masses with
irregular surfaces and the histological examination
showed a partly older and a partly fresh thrombus
(Fig. 2). The patient experienced no post-operative
complications.
Post-operative laboratory tests showed LA
activity without anticardiolipin antibodies, support-
ing the diagnosis of primary antiphospholipid syn-
drome [2]. The patient began treatment with oral
anticoagulation, international normalized ratio
(INR) levels 2–3. The patient was discharged from
the hospital 29 days after surgery, on a regimen of
warfarin (INR 2–3). At ten month follow-up, he was
symptom-free with long-term anticoagulation ther-
apy and no evidence of intracardiac mass recurrence
on two-dimensional echocardiography was seen
(Fig. 1B).
Figure 1. A. Transthoracic echocardiography shows a polypus mass attached to the apex of the left ventricle (LV),
floating freely during cardiac cycle; B. No evidence of intracardiac mass recurrence at two-dimensional transthoracic
echocardiography at ten month follow-up; RV — right ventricle; LA — left atrium; RA — right atrium.
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Discussion
Antiphospholipid syndrome is defined accord-
ing to the clinical and laboratory criteria. That
means a history of thrombus associated with the
presence in blood of lupus anticoagulant and anti-
cardiolipin antibodies of inmunoblogulin G and/or
immunoglobulin M isotype positive, in medium or
high titers on two or more occasions at least
12 weeks apart [1].
The commonest manifestations of APS are
deep vein thrombosis, pulmonary thromboembo-
lism, stroke, myocardial infarction and spontaneous
abortion.
The commonest echocardiographic findings in
patients with APS are either valve vegetations or
thickening of the valve leaflets. These findings are
more frequent than intracardiac thrombus. The li-
terature reports only a few cases of intracardiac
thrombosis [3, 4] associated with APS, observed in
all cardiac chambers, provoking either pulmonary
or systemic embolism. When intracardiac thrombo-
sis occurs, the differential diagnosis of left ventricu-
lar mass includes tumor and thrombus.
Intravenous administration of the new gener-
ation contrast agents during a bedside echocardio-
graphic study has been successfully used to distin-
guish between intracardial masses by evaluating
their vascularity. Thrombus is considered an ‘avas-
cular’ structure, so it does not reveal perfusion,
unlike a malignant tumor which presents increased
vascularity due to higher microvascular density [5].
The commonest primary cardiac tumor is
myxoma. Five per cent of myxomas arise in the left
ventricle. In our patient, without clinical history of
APS, a left ventricular myxoma diagnosis was con-
sidered.
Left ventricular thrombi can develop in sever-
al situations. First, they may be associated with wall
motion abnormalities, but our patient had normal
regional left ventricular function.
The risk of intracardiac thrombosis and/or
thromboembolism is increased in patients who
show positive test results for LA activity. This was
demonstrated in our patient, after surgery.
Venous thrombosis and pulmonary embolism
are also more common in those with LA activity,
while coronary, cerebrovascular, and peripheral
arterial events are more likely in those with ele-
vated levels of IgG or IgM anticardiolipin antibo-
dies [6].
Patients who have primary APS can develop
intracardiac thrombus, as did our patient. Pre-ope-
rative investigations cannot differentiate such
a thrombus from a myxoma, and the diagnosis was
made post-operatively.
It remains unknown whether prolonged
heparin administration, thrombolysis, high-intensi-
ty anticoagulant with warfarin or a surgical excision
is the best therapeutic approach.
Nonetheless, the great size of the mass and its
free-floating appearance on two-dimensional
echocardiography, the history of hemiparesis and
the peripheral embolism, which seemed to place our
patient at high risk for recurrent systemic embo-
lism, led us to choose surgical excision. Moreover,
the pathological features of an older thrombosis,
which could constitute the nucleus for further fresh
Figure 2. Histological examination shows an older thrombus with a fibrin network (A) and a fresh thrombus (B) with
minimal vascular or perivascular inflammation (HE 10×).
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thrombus deposition, further supported the surgi-
cal approach.
The mechanism of this intracardiac thrombus
in patients with primary APS would be a hyperco-
agulability state mediated by monocyte tissue fac-
tor expression. This activity results in formation of
a complex between tissue factor and coagulation fac-
tor VII on the cell surface, which activates factor
IX and factor X. Factor X converts prothrombin
to thrombin, the major serine protease leading to
fibrin formation and platelet activation [7].
Some relapsing thrombosis has been reported
despite long-term warfarin treatment. A follow-up
by two-dimensional echocardiography should be
recommended in patients with primary APS [8].
Conclusions
Intracardiac thrombus has been rarely report-
ed as a sequel to antiphospholipid syndrome. Large,
polypoid and mobile left ventricular thrombus mim-
icking myxoma with recurrent systemic embolism
in a patient with primary antiphospholipid syndrome
has not been previously reported. In our patient, the
pre-operative investigations could not differentiate
such a thrombus from a myxoma, and the diagnosis
was made post-operatively.
Patients who have APS are at high risk of de-
veloping intracardiac thrombus. However, the
thrombus can be successfully resected. To preclude
thrombus formation, warfarin treatment is indicat-
ed in all patients with APS.
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